Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : NOXXON announces its participation in two french investor conferences in October 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:18am CEST

Release date- 29092017 - Berlin, Germany - NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it would participate in two conferences focused on institutional investors in October in Paris.

NOXXON will present at the French Financial Analysts Society / Societe Francaise des Analystes Financiers (SFAF) on October 3, 2017 at 10:00am at 135 boulevard Haussmann, 75008 Paris in the 'Salle Hausmann'.

NOXXON will also participate in the CF&B Large & Midcap Event which will take place on the 4th and 5th of October 2017 at the Palais Brongiart, 28 Place de la Bourse, 75002 Paris. NOXXON pharma will be available for meetings with institutional investors.

Contact:

Tel: +49 (0) 30 726 247 0

Email: [email protected]

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immunooncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy).

NOXXON's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12 (olaptesed pegol), which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Merck & Co.'s anti-PD-1 checkpoint-inhibiting antibody Keytruda (pembrolizumab) in pancreatic and colorectal cancer. The clinical trial testing NOX-A12 as monotherapy and in combination with Keytruda is being conducted at one of the leading centers for cancer research and treatment, the National Center for Tumor Diseases in Heidelberg, Germany. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, the Netherlands and its office in Berlin, Germany.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
11:09pDJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
06:45p MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/19 ONCOSEC MEDICAL : Initiates Registration Directed Clinical Trial, KEYNOTE-695, o..
10/19 MERCK FOUNDATION : Launches Five-Year Initiative to Improve Diabetes Care for Vu..
10/19DJMERCK AND : Chenault Among Few Black CEOs -- WSJ
10/19 BERGENBIO : Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB3..
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
10/18 MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
More news
News from SeekingAlpha
01:44p The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
12:18p Merck to lay off 1,800 sales reps
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 WHY ARE THESE 6 DOW STOCKS FAIRLY VA : Part 4 Of 5
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
Financials ($)
Sales 2017 40 270 M
EBIT 2017 13 680 M
Net income 2017 5 793 M
Debt 2017 8 103 M
Yield 2017 2,96%
P/E ratio 2017 31,81
P/E ratio 2018 18,99
EV / Sales 2017 4,52x
EV / Sales 2018 4,44x
Capitalization 174 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 9,7%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.88%173 214
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
AMGEN27.41%135 924